Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Jun

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer

Preclinical Research Shows Interferon May Attenuate Neutrophil Response to Cancer Immunotherapy

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia

Relapsed or Refractory Multiple Myeloma Talquetamab Daratumumab

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer